Application of 497-25-6, Because a catalyst decreases the height of the energy barrier, its presence increases the reaction rates of both the forward and the reverse reactions by the same amount.497-25-6, Name is Oxazolidin-2-one, molecular formula is C3H5NO2. In a article，once mentioned of 497-25-6
Emerging drugs for nosocomial pneumonia
Introduction: Hospital-acquired pneumonia (HAP) is one of the leading nosocomial infections worldwide and is associated with an elevated morbidity and mortality and increased hospital costs. Nevertheless, prompt and adequate antimicrobial treatment is mandatory following VAP development, especially in the face of multidrug resistant pathogens. Areas covered: We searched Pubmed and ClinicalTrials.gov site reports in English language of phase III clinical trials, between 2000?2016 referring to the antibiotic treatment of nosocomial pneumonia. We provide a summary of latest approved drugs for HAP and emerging drugs with potential indication nosocomial pneumonia. Expert opinion: There are several promising compounds on their way, as tedizolid-a new oxazolidone, iclaprim-a novel drug, related to trimethoprim, plazomicin-a new aminoglycoside and two combinations of ceftazidime/avibactam and ceftolozane/tazobactam against MDR bacteria, especially against MRSA and Gram-negative ESBL bacteria.
A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 497-25-6
Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H748NO – PubChem